Revance to Participate in the Needham 22nd Annual Healthcare Conference

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (Nasdaq: RVNC), today announced that the company will participate in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17 – 20, 2023. Chief Financial Officer, Tobin Schilke, is scheduled to participate in a fireside chat on Tuesday, April 18, at 12:45 P.M. ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that elevate patient and physician experiences. Revance’s aesthetics portfolio of expertly created products and services, including DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the RHA® Collection of dermal fillers, and OPUL®, the first-of-its-kind Relational Commerce platform for aesthetic practices, deliver a differentiated and exclusive offering for the company’s elite practice partners and their consumers. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection, which will compete in the existing short-acting neuromodulator marketplace. Revance’s therapeutics pipeline is currently focused on muscle movement disorders including evaluating DAXXIFY® in two debilitating conditions, cervical dystonia and upper limb spasticity.

Revance is headquartered in Nashville, Tennessee, with additional office locations in Newark, Pleasanton and Irvine, California. Learn more at www.Revance.com, www.RevanceAesthetics.com, www.DAXXIFY.com, or connect with us on LinkedIn.

“Revance” and the Revance logo, DAXXIFY®, and OPUL® are registered trademarks of Revance Therapeutics, Inc.
Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230405005155/en/

Investors
Revance Therapeutics, Inc.:
Jessica Serra, 510-279-6886
[email protected]
or
Gilmartin Group, LLC.:
Laurence Watts, 619-916-7620
[email protected]

Media
Revance Therapeutics, Inc.:
Sara Fahy, 949-887-4476
[email protected]

Source: Revance Therapeutics, Inc.

You May Also Be Interested In

• Alibaba Group Announced Pricing of HK$80 Billion Placing of New Shares in Hong Kong
• pixelgrinder Announces Second Full-Length Album “White Mask” for September 25 Release
• Latest Crypto News: Apeing’s Upcoming Presale Hype Joins Tron and Cardano’s Rising Activity